



COURTESY FORM PTO - 1449 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT				ATTORNEY DOCKET NO.: MEE-002 APPLICANTS: Miller <i>et al.</i> SERIAL NO.: 09/780,142 FILING DATE: February 9, 2001 EXAMINER: Huynh, P. GROUP: 1644			
---	--	--	--	---	--	--	--




U.S. PATENT DOCUMENTS							
EXAM. INIT.	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE	

FOREIGN PATENT DOCUMENTS									
EXAM. INIT.	DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)	

OTHER ART, JOURNAL ARTICLES, ETC.		
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)	
PNT	C133	Gauthier <i>et al.</i> , "Safety and Efficacy of Intravitreal Injection of rhuFab V2, an Anti-vascular Endothelial Growth Factor (VEGF) Antibody Fragment, in Combination With Verteporfin PDT on Experimental Choroidal Neovascularization," <u>ARVO Poster</u> , May 2002.
1/	C134	Gauthier <i>et al.</i> , "Safety and Efficacy of Intravitreal Injection of rhuFab VEGF in Combination With Verteporfin PDT on Experimental Choroidal Neovascularization," <u>ARVO. The Association for Research in Vision and Ophthalmology</u> (Oasis, Online Abstract Submission and Invention System, Program Planner, Presentation # 566), May 2002.
↓	C138	Heier <i>et al.</i> , "rhuFAB V2 (an Anti-VEGF Antibody Fragment) in Neovascular AMD: Safety and Tolerability of Multiple Intravitreal Injections - Preliminary Data from a Single Center," <u>ARVO Poster</u> , May 2002.

EXAMINER	DATE CONSIDERED
	3/13/06

FORM PTO - 1449				ATTORNEY DOCKET NO.: MEE-002					
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT				APPLICANTS: Miller <i>et al.</i>					
				SERIAL NO.: 09/780,142					
				FILING DATE: February 9, 2001					
				EXAMINER: Huynh, P. GROUP: 1644					
U.S. PATENT DOCUMENTS									
EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE		
<i>Pst</i>	A14	5,171,749	12/15/92	Levy <i>et al.</i>	514	410	06/20/91		
	A15	6,162,242	12/19/00	Peyman	607	88	01/21/99		
	A16	6,899,723	05/31/05	Chen	607	88	07/13/01		
	A17	2003-0175282	09/18/03	Miller <i>et al.</i>	424	133	05/05/03		
✓	A18	2003-0185834	10/02/03	Miller <i>et al.</i>	424	133	05/05/03		
FOREIGN PATENT DOCUMENTS									
EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
OTHER ART, JOURNAL ARTICLES, ETC.									
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)								
<i>Pst</i>	C170	Blaauwgeers <i>et al.</i> , "Polarized Vascular Endothelial Growth Factor Secretion by Human Retinal Pigment Epithelium and Localization of Vascular Endothelial Growth Factor Receptors on the Inner Choriocapillaris," Am. J. Pathology 155(2): 421-428, 1999.							
	C171	Husain <i>et al.</i> , "Safety and Efficacy of Intravitreal Injection of Ranibizumab in Combination with Verteporfin PDT on Experimental Choroidal Neovascularization in the Monkey," Arch Ophthalmol, 123: 509-516, 2005.							
✓	C172	Witte <i>et al.</i> , "Monoclonal antibodies targeting the VEGF receptor-2 (Flk/KDR) as an anti-angiogenic therapeutic strategy," Cancer and Metastasis Reviews 17: 155-161, 1998.							
EXAMINER					DATE CONSIDERED				
<i>Pst</i>					3/13/06				